Compare GSAT & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSAT | CYTK |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 10.7B |
| IPO Year | 2006 | 2004 |
| Metric | GSAT | CYTK |
|---|---|---|
| Price | $82.38 | $73.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 19 |
| Target Price | $70.50 | ★ $89.26 |
| AVG Volume (30 Days) | 627.2K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $112,660,000.00 | $13,368,000.00 |
| Revenue This Year | $10.31 | $7.37 |
| Revenue Next Year | $15.93 | $310.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.36 | $47.22 |
| 52 Week High | $84.85 | $88.31 |
| Indicator | GSAT | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 45.18 |
| Support Level | $80.90 | $73.34 |
| Resistance Level | $82.10 | $79.73 |
| Average True Range (ATR) | 0.65 | 2.35 |
| MACD | -0.08 | 0.05 |
| Stochastic Oscillator | 47.88 | 43.07 |
Globalstar Inc is a telecommunications company that derives revenue from the provision of mobile satellite services. Mobile satellite services, including voice and data communications services to retail, business, and governmental customers, as well as wholesale satellite capacity services. The company provides communications services such as two-way voice and data transmission. In addition, one-way data transmission is also offered. Both services are offered using mobile or fixed devices. The company is the owner of satellite assets. It has one reportable segment: the MSS business. The company generates the vast majority of its revenue within the United States.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.